Article Details
Retrieved on: 2024-05-25 22:14:30
Tags for this article:
Click the tags to see associated articles and topics
Summary
The article outlines the clinical trial results of atrasentan for treating IgA nephropathy, a kidney disease. It highlights Novartis' commitment to developing Information Technology-based solutions for managing various kidney diseases through targeted therapies like atrasentan.
Article found on: www.prnewswire.com
This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here